IL6R and type 2 diabetes mellitus: One additional minor allele of the IL6R SNP rs7529229 (corresponding to the effect of taking tocilizumab 4–8 mg/kg every 4 weeks) was suggestively associated with a reduced risk of type 2 diabetes (OR 0.97, 95% CI 0.94, 1.00), which implied a possible role of IL-6 receptor blockade in type 2 diabetes prevention.